Aims To determine the proportion of people with diabetes who have HbA 1c measured, what proportion achieve an HbA 1c level of < 58 mmol/mol (7.5%), the frequency of testing and if there was any change in HbA 1c level in the year before and the year after an incident stroke.
Introduction
After experiencing a stroke, people with diabetes are more likely to have another stroke and to have earlier mortality than those who have not had a stroke [1] . The National Health and Nutrition Examination Survey study [2] has shown that, over a period of 9 years (between 1999 and 2008), there was an improvement in several cardiovascular risk factors including HbA 1c in people diagnosed with diabetes. Diabetes is common in patients with stroke but guidelines do not give specific recommendations concerning diabetes management after stroke, either in terms of frequency of HbA 1c testing or blood glucose control. What level of glycaemic control is achieved after a stroke and whether lowering of HbA 1c levels after a stroke through aggressive blood glucose control is beneficial is not known [3] .
We aimed to determine the proportion of people with diabetes who have HbA 1c measured, what proportion achieve an HbA 1c level of < 58 mmol/mol (7.5%), the frequency of testing and if there was any observed change in HbA 1c level in the year before and after an incident stroke.
Methods
The Secure Anonymised Information Linkage (SAIL) databank stores hospital data for the whole of Wales, as well as for~65% of Welsh general practices [4] . Once a general practice has voluntarily signed up to SAIL, data submission are facilitated annually. All historical general practice records are uploaded and made available for retrospective analysis, with patient records being present based on the period of registration with the given practice. Nationwide Welsh hospital data are submitted annually to SAIL and processed by the NHS Wales Informatics Service.
A study window between 2000 and 2010 was used to select incident cases of stroke in Welsh hospitals, identified using International Classification of Diseases-10 codes I61 and I64. These individuals were then linked to data available in general practice records contained within SAIL by an encrypted National Health Service (NHS) number, where version 2 READ codes C10 and further subcodes (e.g. C101) were used to identify patients who had diabetes before their incident stroke, and READ codes 42W (including subcodes) and 44 TB, 44TC, 44TL were used to select HbA 1c measurements in the year before and after the incident stroke. We only included patients who survived at least 1 year after stroke.
A control group was formed by selecting (without replacement) at least eight patients per case, matched by age and sex from the Welsh population that had diabetes. None of the control patients had reported any admission for stroke.
We determined the frequency of HbA 1c testing and change in HbA 1c levels in the first year after stroke, using one-sample t-tests (unpaired). The frequency group was a subset of the case-control group where each person survived the first year after stroke and was registered with a SAIL general practitioner for the years before and after stroke, and the HbA 1c analysis was a subset of the frequency group, where all persons had at least one HbA 1c measurement in the year before and after stroke. Finally, estimation was made of the proportion of both cases and controls who achieved an HbA 1c measurement at or below 58 mmol/mol (7.5%).
Results
A total of 1741 patients met our inclusion criteria. Patients with diabetes had a higher mean frequency of HbA 1c testing by their general practitioner before an incident stroke, with no change in frequency in the year after stroke. The patients with diabetes who had not experienced a stroke underwent a small increase in frequency of testing. These results are shown in Table 1 .
In those who had experienced a stroke, the HbA 1c level was 4 mmol/mol (0.4%) higher before their stroke compared with the control group (P < 0.001). A year after the index stroke, a decrease in HbA 1c levels was observed in those in the case group, in both men and women, compared with the control group, where no change was observed ( Table 2) .
In the year before the study commenced, 55.0% of cases had an HbA 1c ≤ 58 mmol/mol (7.5%) compared with 65.2% of controls, with the equivalent figures in the year after the stroke being 62.5% of cases and 65.3% of controls.
Discussion
Using the SAIL databank we examined diabetes control and monitoring in a large and generalizable cohort of stroke survivors. The frequency of diabetes testing was higher in patients with diabetes who had experienced a stroke before and after their incident stroke compared with control patients, but the frequency of testing did not increase after their stroke. We found glucose control, measured using both the HbA 1c level and the percentage of patients achieving a target HbA 1c level, improved significantly in the year after a stroke and became similar to that in patients with diabetes who had not experienced a stroke.
We found that the annual rate of testing was 78% in the year preceding stroke and 76% in the year after stroke. This is lower than the UK national audit results for patients with Type 2 diabetes, where 91.3% had an annual HbA 1c in 2011-2012 [5] . The discrepancy may be explained by two factors. Firstly, we were not able to detect HbA 1c measured in secondary care, a limitation of the SAIL databank. The national audit estimated secondary care HbA 1c measures to account for just under 4% of their results. Secondly, our results are from the time period 2006-2010 compared with the latest national diabetes audit from 2011 to 2012. It is likely that, partly as a result of the audit itself, the frequency of testing has increased in this period in the UK as a whole. Our data support that by showing an increase in HbA 1c testing in the control group.
The patients with diabetes who had experienced a stroke had a higher baseline rate of testing in the year preceding their stroke than the control group. This may reflect clinical concern regarding their HbA 1c levels, which we found to be, on average, 4 mmol/mol (0.4%) higher in the year before their stroke than those of the control group.
What's new?
This is the first description of HbA 1c assessment in the year before and the year after an incident stroke.
The study considers the Secure Anonymized Information Linkage (SAIL) databank, which is a large epidemiological resource, representative of the Welsh population.
HbA 1c levels were found to decrease in the year after a stroke by 4 mmol/mol (0.4%).
Despite falls in HbA 1c levels the frequency of HbA 1c testing did not change in the year after a stroke.
The rates of HbA 1c testing after stroke did not increase. UK national guidelines recommend monitoring of HbA 1c every 2-6 months in patients with Type 2 diabetes [6] . Our findings were clearly below these guidelines. There are several possible explanations. Stroke frequently causes disability and reduced healthcare access, meaning that HbA 1c testing may not be easily available for all. Additionally, in those people with major disability, or those who receive endof-life care, frequent HbA 1c monitoring may not be indicated
We also aimed to assess change in HbA 1c levels after stroke. We found the HbA 1c level was reduced substantially after a stroke, reaching the same level as in patients without stroke. A drop of 4 mmol/mol (0.4%) after a stroke will lead to better diabetic outcomes [7] and indicates an improved level of diabetes control overall. What level of post-stroke HbA 1c represents the optimum level after a stroke is still to be determined and warrants future study. The present study only considered HbA 1c levels in patients who survived for 1 year after stroke and not in those who died; therefore, this finding is more likely to represent improved control of diabetes rather than a higher premorbid HbA 1c level in patients who died from their stroke.
The national audit of diabetes care, which has already been discussed, showed that 65.8% of patients tested had an HbA 1c level within the 58 mmol/mol (7.5%) range or lower. This level reflects the definition of adequate control levels set by UK guidelines [6] . To aid comparison, the present study used this threshold. There was a marked rise in the number of patients with diabetes achieving this level in the year after stroke, from 55 to 62.5%, in the present study sample.
Other possible reasons for the levels of HbA 1c found are inadequate monitoring or failure to optimize treatment. Evidence exists relating to inadequate diabetic control after stroke. A case-control study was performed comparing 2830 patients with cerebrovascular disease against 24886 patients without [8] . There were established diagnoses of diabetes in 982 patients in the stroke survivor group and in 5163 patients in the control group. A total of 895 patients (88.3%) in the stroke survivor group were receiving treatment, but only 59.2% of this group had adequate control.
Post-stroke HbA 1c levels may also be affected by certain factors directly related to stroke disease itself. Empowering patients, through knowledge, can help individuals take control of their diabetes management [9] . In people with cognitive impairment after stroke this is likely to be more challenging and to contribute to inadequate risk factor control. Carers or family members are relied upon in this situation to help encourage and monitor medication concordance, promote lifestyle advice and support access to healthcare professionals.
In the present examination of a large national database, we found that HbA 1c levels improved in people who had a stroke. It appeared that these individuals represented a highrisk population before their stroke, with a higher baseline frequency of HbA 1c testing, which did not change. The degree of HbA 1c testing was substantially below the recommended UK guidelines. Future studies should consider HbA 1c levels in patients with diabetes who have had a stroke who are left severely disabled after their stroke to assess whether the improvement in HbA 1c level and static level of testing observed in the present study were influenced by the healthcare needs of this group of stroke survivors.
Funding sources
None.
